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Abstract
Multiple Sclerosis (MS) is a demyelinating autoimmune disease of the central nervous system (CNS) with a presumed
autoimmune etiology. Approved treatments for MS are immunoregulatory and are able to reduce the inflammatory
components of the disease. However, these treatments do not suppress progressive clinical disability. Approaches that
directly protect myelin-producing oligodendrocytes and enhance remyelination are likely to improve long-term outcomes
and reduce the rate of axonal damage. Galanin (GAL) is a bioactive neuropeptide that is widely distributed throughout the
nervous system and has diverse neuromodulatory effects. In this study, using the cuprizone (CPZ) demyelination model of
MS, we demonstrate that GAL has pronounced neuroprotective effects with respect to demyelination and remyelination.
Using our GAL transgenic mouse (GAL-Tg), we identified a novel attenuation of OLs against CPZ induced demyelination,
which was exerted independently of progenitor cells. Alleviation of myelin breakdown in the GAL-Tg mice was observed to
be significant. Furthermore, we observed changes in the expression of the GAL receptor GalR1 during the demyelination
and remyelination processes. Our data strongly indicate that GAL has the capacity to influence the outcome of primary
insults that directly target OLs, as opposed to cases where immune activation is the primary pathogenic event. Taken
together, these results suggest that GAL is a promising next-generation target for the treatment of MS.
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Introduction
Multiple Sclerosis (MS) is an inflammatory demyelinating
disease of the brain and spinal cord with a presumed autoimmune
etiology. The pathology of MS features focal areas of inflamma-
tory infiltration and demyelination in which oligodendrocytes
(OLs) – the myelinating cells of the central nervous system (CNS) –
are depleted [1]. During the early stages of MS, some repair of this
damage is still possible, likely due to partial remyelination [2]
initiated by surviving or newly formed OLs (generated from
progenitor cells) [3]. In the primary and secondary progressive
forms of MS, a high degree of cortical demyelination has been
observed [4,5], but active cortical lesions show only mild
lymphocytic infiltrates [6]. All approved treatments for MS are
immunoregulatory, which are able to reduce the inflammatory
component of the disease. Unfortunately, these treatments are not
effective against progressive clinical disability. However, new
treatments that target OLs and myelin sheaths have come under
serious consideration [7,8]. Approaches that directly protect
myelin-producing OLs and enhance remyelination may improve
long-term outcomes and reduce the rate of axonal damage in MS
patients.
Galanin (GAL) is a 29-amino-acid neuroendocrine peptide that
is widely distributed throughout the rat, mouse and human CNS,
where it functions alongside more ‘‘classical’’ neurotransmitters
[9,10]. It has been demonstrated that GAL acts as a survival and
growth-promoting factor for different types of neurons in the
peripheral nervous system (PNS) and the CNS [11]. GAL has also
been implicated in the control of neurogenesis (i.e., the
proliferation, differentiation and/or migration of neural stem
cells) in both normal and injured brains [12,13,14,15]. High levels
of GAL and GAL receptors (GalR1 and GalR2) are expressed in
the subventricular zone (SVZ), the rostral migratory stream
(RMS), the subgranular zone of the dentate gyrus (SGZ) and in
oligodendrocyte precursor cells (OPCs) of the corpus callosum
[12,13,16,17,18]. Recently, it has been demonstrated that GAL is
markedly upregulated in MS lesions including shadow plaques in
post-mortem brain tissue from chronic MS sufferers exclusively in
microglia [19], although not all microglia were galanin positive. In
the same study, GAL was also uperegulated in the CNS of mice
with acute inflammation in the EAE model, although here it was
exclusively in oligodendrocytes.
One of the best characterized demyelinating mouse models is
that of C57BL/6J mice with cuprizone (CPZ), a copper chelator,
added to their diet [20]. CPZ, when given in small doses, acts as a
neurotoxin that specifically induces the death of OLs and causes
inflammation in the resulting demyelinated areas; these effects are
reversible, and the removal of CPZ from the mouse feed permits
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33901remyelination. The lesions that occur in the brains of CPZ-treated
mice are similar to type III and type IV lesions observed in MS
[21]. In this mouse model, focal inflammation and demyelination
occurs in the brain, however, T lymphocytes do not appear to play
a role in these processes [20].
We have previously reported the creation of a GAL-Tg mouse
in which GAL is over-expressed in the anterior pituitary gland
causing circulating GAL levels to be chronically elevated [22,23],
and to a much lesser extent prolactin (PRL) and growth hormone
(GH). In the present study, using the CPZ-mediated demyelination
model of MS, we demonstrate that GAL has pronounced
neuroprotective effects with respect to demyelination and
remyelination and that it directly prevents OL death. Moreover,
we also found changes in the expression of the GAL receptor
GalR1 during the demyelination and remyelination processes.
These results suggest that GAL and/or GAL receptors could
represent next-generation therapeutic targets for the treatment of
MS.
Results
Effects of the over-expression of GAL on body weight
Initially (at 8–9 weeks of age) Gal-Tg mice were heavier than
WT mice, with average body weights of 29.9 6 4.3 g and 24.9 6
2.4 g, respectively (mean 6 SD).By six weeks later, Gal-Tg and
WT mice had gained 27.6618.3% and 21.3613.5%, respectively,
of their body weight compared to their initial weight(Fig. 1A). In
comparison, after treatment with CPZ diets, both Gal-Tg and WT
mice lost a significant amount of body weight in the first week. Tg
mice lost approximately 5% of their weight after one week, while
WT mice lost approximately 10% of their weight after two weeks.
However, Tg mice started to gain weight after one week on the
diet, while WT mice continued losing weight until the third week
(Fig. 1B). Following withdrawal of the CPZ challenge, mice of both
genotypes gained weight immediately (but at different rates)
(Fig. 1B). There was a statistically significant difference in the rate
of body-weight increase between Gal-Tg and WT mice. Two-way
mixed-measures ANOVA revealed a significant interaction
(F(6,138)=9.83, p,0.0001) between normal body-weight growth
rate and genotype, indicating that the rate of body-weight growth
was dependent on genotype. Another two-way mixed-measures
ANOVA analysis revealed that, during CPZ challenge, there was a
significant influence of genotype on changes in body weight.
CPZ-induced demyelination in MBP staining is
attenuated in GAL-Tg mice
Consistent with previous studies [20,24], our findings revealed
that CPZ challenge caused significant loss of myelin in WT mice,
particularly in the CC and in the junction area between the CC
and the cerebral cortex (Fig. 2B, Fig. 2b). However, this myelin
breakdown was significantly reduced in Gal-Tg mice (Fig. 2E,
Fig. 2d). In Gal-Tg mice, myelin degradation in the external
capsule of the CC (as demonstrated by the doubled arrow in the
whole brain pictures of Fig. 2b, Fig. 2d) were obviously reduced
compared with WT mice. In WT mice, after six weeks of CPZ-
induced challenge, only a few myelin fibers remained, which were
restricted to layer four of the cortex. On the other hand, both WT
and Gal-Tg mice from the recovery groups showed dense MBP
staining (Fig. 2C, 2F). A two-way ANOVA analysis revealed that
genotype significantly affected MPB staining in the control,
demyelination and remyelination groups (F(2,16)=9.56,
p=0.0019). Post-hoc comparison tests found that Gal-Tg mice
had a significantly greater level of MBP staining (based on the
optical density values) after six weeks of the CPZ challenge. One-
factor ANOVA tests on the WT mouse data revealed that the
CPZ-induced challenge significantly affected the myelin staining
results (F(2,6)=28.86, p,0.001). We also used Luxol Fast Blue
(LFB) staining on normal and CPZ-challenged animals to verify
the IHC results, which showed that the integrity of the myelin
fibers was similar to that observed in the IHC staining (Fig. 2,
images I–IV). Western blotting analysis of MBP protein level
changes were consistent with the changes in MBP staining (data
not shown).
Increased circulating GAL alleviates demyelination-
related pathogenesis
The loss of mature OLs was attenuated in GAL-Tg mice. We
first examined the mature OLs that survived the CPZ-induced
challenge. IHC staining demonstrated that, in control animals,
there were widely distributed GST-p positive cells in the cortex
(data not shown) and linearly distributed cells in the CC (Fig. 3A,
3D). As expected, after six weeks of CPZ-induced challenge in WT
Figure 1. The effect of GAL over-expression on body weight. Body weight was measured at the age of 8–9 weeks old as the starting point
0 w. The raw body weight growth in normal control groups (A) and the CPZ-treated groups (B) is shown. Both the cuprozone groups and the
cuprizone-challenge plus 3-week recovery groups were measured at the same time. Data are expressed as the mean 6 SEM. (n=12–17 per group).
*p ,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0033901.g001
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small number of positive cells remained in the cortical areas
(restricted to cortex layer four). However, in Gal-Tg mice, there
were still many positive cells after six weeks of CPZ-induced
challenge (Fig. 3E, 3H). Furthermore, many positive cells could be
observed in WT mice from the recovery group, while no obvious
differences were observed in Gal-Tg mice between the demyelin-
ation and recovery groups (Fig. 3E, 3F). A two-way ANOVA test
on the cell numbers revealed that genotype significantly influenced
the number of GST-p-positive cells under the control, demyelin-
ation and recovery conditions (F(2,12)=4.40, p=0.0370). Post-
hoc comparison tests found a significant difference between WT
and Tg mice from the 6wCPZ group (p,0.01). A one-way
ANOVA test on the WT groups showed that the mean number of
positive cells was significantly different across the groups, and
Tukey’s test revealed significant differences between the WT CLT
versus the WT6wCPZ groups (p,0.001) and the WT 6wCPZ
versus the WT 6wCPZ+3wR groups (p,0.001). However, a one-
Figure 2. Over-expression of GAL blocks CPZ-induced myelin breakdown. (A)–(F) are photographs of the cerebral cortex and the CC, while
(a)–(d) are the photographs of whole brain. Both Tg and WT mice were given 0.3% CPZ for six weeks (6wCPZ), and then the two groups of mice were
allowed to recover for three weeks on a normal food diet (6wCPZ+3wR). Mice brains were processed for IHC staining using an antibody against MBP.
Consistent with previous studies, we found extreme demyelination in WT mice after six weeks of CPZ challenge: compare (B) and (b) with the control
groups (A) and (a). However, MBP staining of Tg mice brains, (E) and (d), indicated that myelin breakdown was not significantly different compared
with controls, (D) and (c). After three weeks on a normal diet, the WT mice recovered well (as expected) (C). To verify the IHC staining results, we also
used luxol fast blue staining on WT CLT (I), WT 6wCPZ (II), Tg CLT (III) and Tg 6wCPZ (IV) samples (6 mm paraffin sections). The bar graphs represent
the measurements of optical density of MBP IHC staining in the cerebral cortex and the CC areas. Arrows show the aca area that was used for color-
intensity standardization. Data are expressed as mean 6 s.e.m values. (n=3–5 per group). ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0033901.g002
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groups, although the results showed a trend indicating impairment
after the CPZ-induced challenge.
Proliferation and accumulation of OPCs were low in the
Gal-Tg mice after CPZ-induced challenge
The distribution of OPCs was revealed by IHC for PDGFR-a,
one of the two commonly used cell markers for OPC identity.
Under normal conditions in the control groups, there were few
PDGFR-a-positive cells in the brains of WT and Tg mice (Fig. 4A,
4D). After CPZ-challenge, the number of PDGFR-a-positive cells
began to increase in the CC of WT mice (Fig. 4B). Furthermore,
this positive staining was significantly higher in the brains of WT
mice from the recovery group (Fig. 4C) (p,0.05). In contrast with
WT mice, the numbers of PDGFR-a-positive cells in Tg mice
were similar among the different groups (Fig. 4D–F).
In GAL-Tg mice the invasion of CPZ-induced reactive
astrogliosis was restricted
Without any experimental challenge, most of the GFAP positive
cells were limited to the CC area in both WT and Tg mice brains
As expected, after the CPZ-induced challenge, increased numbers
Figure 3. Increased levels of galanin attenuated CPZ-induced oligodendrocyte loss. Mature oligodendrocytes were detected with IHC
using a GST-p antibody. Photographs (A–F) were taken from the knee region of the CC, and (G) and (H) are examples of the full-size pictures taken of
WT and Tg brains from the 6wCPZ group. The three CC images in the upper panels (A–C) show the WT mice from the CTL, 6wCPZ and 6wCPZ+3wR
groups, and the three images in the middle panels (D–F) show the Tg mice from the same groups. In (A–F), high-magnification micrographs were also
taken of the CC area using an oil-immersion lens, as shown in the inserts. (I) A bar chart displaying the numbers of GST-p positive cells, which were
counted manually. **p,0.01, ***p,0.001, n=3 in each group. The longer scale bar represents a length of 200 mm and the shorte scale bar represents
500 mm.
doi:10.1371/journal.pone.0033901.g003
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brain in both WT and Tg mice. More precisely, the distribution of
the reactive astrocytes in WT mice was diffused through all layers
of the cerebral cortex, but in Tg mice, the invasion of reactive
astrocytes was limited within layer four of the cerebral cortex, i.e.,
no labeling was seen in cerebral cortex layers five and six. In the
recovery groups, the reactive astrogliosis (in terms of the density of
staining) in WT mice was reduced, although the distribution was
still dispersed in the cortex, but the diffusion in Tg mice were still
restricted in the limited regions.
The GalR1 receptor is more highly expressed during the
demyelination and remyelination (recovery) phases
The expression levels of GAL receptors were normalized to the
levels observed in WT mice from the control group. The
expression levels of GalR1 were 2.7- and 6.4-fold higher in WT
and Tg mice, respectively, in the demyelination groups. The
expression levels of GalR1 were increased even further (2.9- and
5.8-fold higher in WT and Tg mice, respectively) in the recovery
groups (Fig. 5A). In contrast with GalR1 expression, the
expression of GalR2 was increased 1.4- and 2.1-fold in WT and
Tg mice, respectively, in the demyelination groups; expression of
GalR2 increased 2.2- and 3.3-fold in WT and Tg mice,
respectively, in the recovery groups (Fig. 5B).
Discussion
GAL has diverse biological functions in the nervous system, and
the potential for its involvement in myelin development had been
demonstrated by Shen et al. [15]. The present study reveals a
Figure 4. Increased number of PDGFR-a positive cells in WT mice that underwent the CPZ-induced demyelination challenge. WT and
Tg mice were given CPZ challenge for six weeks (6wCPZ, B and E) while the control mice (CLT, A and D) received normal CPZ-free rodent chow. After
six weeks of challenge, two groups of animals (6wCPZ+3wR, C and F) were allowed to recover for three weeks on a normal CPZ-free diet. The bar
graph shows the results of the optical-density measurements of the PDGFR-a-positive cells; a significant difference was observed between the
6wCPZ+3wR WT and Tg groups. The scale bar represents 200 mm in the low-magnification. Data are expressed as mean 6 SEM values (n=3 per
group). *p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0033901.g004
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cuprizone induced demyelination.
Unlike other GAL transgenic models, the circulating levels of
GAL in our Gal-Tg mice were 10-fold higher than those observed
in WT mice [22]. This dramatic increase in circulating GAL
provides a unique tool to study its neuromodulatory role. The
Blood-Brain Barrier (BBB) was once assumed to be impermeable
to peptides. However, it is now widely accepted that peptides are
capable of crossing the BBB by both non-saturable and saturable
transport mechanism to the extent that they can affect events in
the CNS. There exist several potential means whereby circulating
GAL could enter the brain. First, the circumventricular organs
could provide a broad passageway [25]. Additionally, active
transport mechanisms have been described elsewhere, which also
protect the substances from rapid degradation [26]. Furthermore,
GAL has been shown elsewhere to cross the BBB, as intravenous
administration of GAL has quick acting anti-depressant activity
and affects sleep EEG recordings [27].
The present study indicates that GAL-receptor signaling plays a
key role in modulating CPZ-induced demyelination. Using our
GAL over-expressing transgenic mouse model, we identified a
novel attenuation of OLs against CPZ-induced demyelination, and
we found that this influence was exerted independently of
progenitor cells. Alleviation of myelin breakdown in the GAL-
Tg mice was observed to be significant.
Myelin basic protein (MBP) is a structural protein of myelin
sheath. Furthermore, it is believed to be a vitally important
functional protein for myelin assembly and maintenance [28].
MBP IHC staining, which was used in the present study, is a
common method for quantitatively measuring myelin sheath levels
[29]. Thus, after a six-week exposure to CPZ challenge, the
significant loss of MBP staining in WT mice is indicative of severe
demyelination, and the attenuation of MBP-staining loss in Tg
mice suggests an alleviation of demyelination. The DAB-dye-based
IHC staining results were also verified using Luxol Fast Blue
staining, another commonly used histological myelin staining
method. The loss of MBP protein in WT mice was also
demonstrated by western blotting with the same antibody used
for the IHC staining (data not shown).
Because the experimental demyelination induced by CPZ is
caused by the apoptosis of OLs [20], we next examined the
number of mature OLs in the different groups. GST-p is a myelin-
and OL-associated enzyme in the brain that is used as a biomarker
for mature OLs [30,31]. For the first time, we show that (with
respect to CPZ-induced demyelination) the loss of GST-p positive
cells observed in WT mice was greatly alleviated in our GAL- Tg
mice. Interestingly, the distribution of protected OLs in the
neocortex of the GAL-Tg mice corresponded to the GAL-stained
cells in the same area, indicating a direct protective effect of GAL
on OL survival. In this study, we also found that the
oligodendrocyte precursor cells (OPCs) were highly proliferative
and accumulated in response to CPZ-induced oligodendrocyte
degradation in the WT mice, in contrast to a minimal response in
the Tg mice. It has been suggested that the infiltrating proliferative
OPCs are recruited to reverse the loss of mature OLs by
proliferation and differentiation and that OL death (in the lesions)
is characterized by a repopulation of OPCs prior to new OL
formation [32]. These findings support the hypothesis that the
lower levels of OPC proliferation and accumulation seen in Tg
mice are caused by an improvement in OL survival.
These results provide important insights into the mechanisms by
which GAL-receptor signaling influences the phenotypes of central
nervous system (CNS) demyelination. Our data strongly indicate
that GAL has the capacity to influence the outcome of primary
insults that directly target OLs, as opposed to cases where immune
activation is the primary pathogenic event. This is an important
distinction, as EAE (the principal animal model of central
demyelination) is driven by immune cell (principally T cell)
activation. Evidence has already been provided to suggest that the
influence of GAL in EAE is associated with OLs [19], which is of
particular importance given the fact that OL death can be an early
event in MS (even preceding immune cell infiltration) [33]. Thus,
our study provides evidence for the potential use of GAL as a
therapeutic target of oligodendro-cytopathy in MS and compli-
ments the study of Dr. Wynick’s group.
One limitation of the study is that in our Gal-Tg mouse besides
chronic increase of serum GAL there is an increase, to a much
lesser extent, of PRL and GH that they might act as confounders
to the observed phenotype. While though both hormones have
been described to have an effect on myelination [34,35,36,37], this
effect is mainly through the proliferation of OL progenitors (OPS).
In our study the most pronounced effect in the Gal-Tg is not the
proliferation of OPs, since PDGFR-a-positive cells did not change,
but the attenuation of OLs death. We believe that this effect is
Figure 5. The differential expression of GalR1 and GalR2 in the CC area. RNA samples were extracted from CC areas as demonstrated in
Figure 6. The gene expression levels among the groups were normalized to the WT CLT levels (set equal to 1). (A) The expression of GalR1 among the
groups. (B) The expression of GalR2 among the groups. Data are expressed as the mean 6 SEM values. (n=3–6 per group). * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0033901.g005
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needed to confirm that. Furthermore, the increased lipid levels of
the obese phenotype of our transgenic mice might have also
contributed to an accelerated myelination. Studies in progress are
defining this issue as well.
In the context of the CPZ model (where the BBB is thought to
be intact), the apparent efficacy of increased levels of circulating
GAL [38] provides an important insight into the pharmacody-
namics of this protein. Our data suggest that (in the context of MS)
GAL might be able to protect OLs in regions anatomically distant
from the discrete active plaques where the BBB is actually
disrupted; this could help eliminate progressive neurodegenera-
tion, independent of the degree of acute inflammatory activity.
It is well accepted that GAL exerts its biological effects through
the three G-protein coupled receptors, GalR1, GalR2 and GalR3.
These three receptors activate distinct G-proteins that participate
in different GalR-signaling pathways, which results in diverse
biological functions being activated upon the binding of GAL or
other ligands [39]. In this study, a gene expression assay revealed
that the expression of GalR1 and GalR2 was differentially altered
in the demyelination and remyelination phases, suggesting these
two receptors have distinct roles during these two phases. The
change in GalR1 expression during the initial challenge phase may
be indicative of a protective effect in response to demyelination,
while the trend of GalR2 inrease in the later recovery phase,
although not significant compared to wild type, may imply the
existence of a neurotrophic effect during recovery. Interestingly,
the differential involvement of GalR1 and GalR2 in response to a
pathological challenge has also be observed in seizure develop-
ment – the involvement of GalR1 was found to be important
during the initiation phase, while GalR2 was found to be more
important during seizure maintenance [40]. However, the gene
expression assay in this study does not provide direct evidence
concerning the mechanisms of GalR1 and GalR2 action in the
demyelination and remyelination processes. Further studies are
needed to investigate the roles of these two receptors and their
downstream effects.
In summary, we have provided evidence that elevated
circulating GAL can greatly alleviate CPZ-induced demyelination.
Furthermore, we show that the attenuation of demyelination-
related impairments (from the effect of elevated GAL) was directly
related to a reduction in the death of mature OLs. Gene
expression assays also revealed differential responses of GalR1
and GalR2 to demyelination. These findings strongly support the
hypothesis that elevated circulating GAL can alleviate CPZ-
induced demyelination via GalR1 receptor. Demyelination is the
final pathological downstream event in MS, and it is at the core of
the diverse symptoms and disabilities caused by this disease. Over
the decades, many contributions have been made to the
immunoregulatory treatment of MS. However, new strategies for
myelin protection are considered to be the best hope for next-
generation therapies. Overall, our findings strongly suggest
potential therapeutic effects for GAL, with respect to myelin
protection, in the treatment MS.
Materials and Methods
Experimental animals
All mice, including wild-type (WT; C57BL/6) and homozygous
transgenic mice (GAL-Tg) maintained on a C57BL/6, were
housed in the University of Manitoba animal facility in a
temperature controlled environment (20uC under a 12 h light/
dark cycle). Food and drinking water were available ad libitum.
Twenty five male WT mice were obtained from Charles River
(Montreal, QC, Canada); GAL-Tg mice were generated as
previously reported [22,23] using a 320 bp fragment of the rat
growth hormone (GH) promoter fused to the full-length rat
preprogalanin cDNA clone. Before the initiation of the experi-
ment, homozygous Gal-T mice were backcrossed to wild type WT;
C57BL/6 from Charles River and brought again to homozygosity.
Thirty six GAL-Tg male mice were used in this study, to avoid the
effects of fluctuating steroid hormones in female mice on the
expression of GAL [23,41]. 3–6 mice were used per group and the
whole experiment was repeated twice. All procedures were in
accordance with the Animal Protocol Review Board of the
University of Manitoba which has approved this study under the
protocol #10-013/1 (principal investigator Dr.Vrontakis). Cupri-
zone-induced demyelination
To induce demyelination, both WT and GAL-Tg mice at 8–9
weeks of age were fed with a diet containing 0.3% (w/w) CPZ
(C9012-25G, Sigma-Aldrich) for six weeks. No lethality was
observed due to treatment. CPZ powder was well blended into
milled LabDiet rodent chow (ProlabH RMH 3000 5P00, 22.0%
crude protein, 5.0% crude fat, 5.0% crude fiber, 6.0% ash, and
2.5% added minerals) using a food processor (43-1976-0,
KitchenAid), then the blended diet powder was re-pelleted by
extrusion through a 30 ml plastic tube. The CPZ diet was freshly
prepared and given to the mice twice a week while monitoring for
body weight. To allow for remyelination, animals that had
received the CPZ diet were put back on a normal diet for an
additional three wks. The experimental mice were divided into the
following three groups: control (CLT), demyelination (6wCPZ)
and remyelination (6wCPZ+3wR). Body weight and general
behaviors (grooming, activity, etc.) were monitored twice a week.
Immunohistochemistry
For the Immunohistochemistry (IHC) analysis, half of animals
in each group were anesthetized by isoflurane inhalation, perfused
intracardially with 0.1 M Phosphate buffered saline (PBS; pH 7.4)
containing 50 U/ml heparin sodium, followed by 4% parafor-
maldehyde prepared in 0.1 M PBS. The brains were then
dissected out and post-fixed in the same fixation solution at 4uC
overnight, followed by cryoprotective treatment in 0.1 M PBS
containing 30% sucrose at 4uC (until the brains no longer floated).
The dehydrated brains were snap-frozen on dry ice and stored at
280uC until sectioning. Serial coronal sections (25 mm thick) of
the frozen brains were made using the Leica SM2400 sliding
microtome equipped with a freezing plate. The free-floating
sections were then kept in 24-well plates containing 0.1 M PBS at
4uC. Sections corresponding to levels 185–195 of the High
Resolution Mouse Brain Atlas (Sidman et al.; http://www.hms.
harvard.edu/research/brain/atlas.html) were used in this study.
Staining was performed using the avidin-biotin-peroxidase com-
plex technique. Procedures were carried out on a slow shaker at
room temperature, unless otherwise indicated. Briefly, free-floating
sections were washed in 50 mM Tris Buffered Saline (TBS,
pH 7.4) three times (5 min each) followed by pre-treatment with
3% hydrogen peroxide for 30 min. Sections were then washed in
TBS and incubated for 1 h in a blocking solution consisting of 5%
normal goat serum and 0.3% Triton-X100 in TBS. Subsequently,
the sections were incubated in the same blocking solution
overnight at 4uC with primary antibodies (Table 1). After washing
in TBS containing 0.1% Tween-20 (TBST), sections were
incubated with biotinylated secondary antibodies (all secondary
antibodies were purchased from Vector Laboratories, Ontario,
CA) for 1 h, followed by three washes in TBST. Sections were
further treated with the peroxidase-coupled avidin-biotin complex
(ABC Peroxidase Staining Kit, Cat # 32020, Pierce) for 1 h.
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DAB Peroxidase Substrate Kit (3,39-diaminobenzidine; Cat # sk-
4100, Vector Lab). After mounting on the clean pre-coated slides
(Superfrost Plus Microscope Slides, Cat # 12-550-15, Fisher),
sections were then air-dried on a 37uC slide warmer overnight.
The following day, sections were post-treated with a series of
increasing concentration alcohols from 70% to 100%, followed by
two treatments with xylene. Control slides were processed in
parallel with experimental slides using the same agents, except
without primary antibodies. No positive staining was observed in
the control slides.
RNA preparation
All instruments used in the brain dissections were RNase-
decontaminated by wrapping with RNaseZapH (Cat # 9780,
Ambion). Mice were anesthetized by isoflurane inhalation and
were quickly decapitated. The fresh brains were quickly removed
and placed into a stainless-steel mouse-brain holder (Adult Mouse
Brain Slicer Matrix, Cat # BSMAS005-1, ZIVIC Instruments).
On the holder, a 2.5 mm thick coronal slab was made. The first
coronal cut was 5 mm away from the edge of olfactory bulb, and
the second cut was 2.5 mm (5 section slice intervals of the brain
holder) away from the first cut. The selected brain structures (the
corpus callosum and part of the cortex) were then dissected from
the brain slab, using a stereomicroscope on ice (Fig. 6). Isolated
tissues were quickly transferred into 2.0 ml RNase-free microtubes
containing 0.6 ml of ice-cold TRIzol (Cat # 15596026, Invitro-
gen). Total RNA was extracted from each homogenized tissue
sample (processed using Homogenizer Power Gen 125, Generator
Flat 5695, Fisher Scientific) using the phenol/chloroform
extraction protocol provided by Invitrogen (TRIzol Reagent).
Subsequently, the total RNA was purified using the RNeasy Mini
Kit (Cat # 74004, QIAGEN) according to the manufacturer’s
protocol; DNA-decontamination treatment was included. The
purified RNA samples were dissolved in RNase-free water and
were stored at -80uC until processed.
Real-time reverse transcription polymerase chain
reaction
Total RNA was quantified using a spectrophotometer (Nano-
Drop, Cat # ND-1000, Thermo, Fisher Scientific), and 1 mgo f
total RNA was used to generate single-stranded cDNA. The
concentrated total RNA samples were diluted to 0.1 mg/mli na t
10 ml volume. The diluted RNA samples were denatured at 70uC
for 10 min and then added to the reverse transcription (RT)
master-mix (Table 2). For RT, the reaction conditions were as
follows: 25uC for 10 min, 42uC for 50 min, and 72uC for 15 min
with a 0uC hold at the end.
The previously generated cDNA templates were diluted with
50 ml RNase-free water. For qPCR, the primer pairs were
designed and generated by SABiosciences
TM, QIAGEN; the
housekeeping gene GAPDH (Glyceraldehyde-3-phosphate dehy-
drogenase) was used as the internal quantitative control (Table 2).
Each PCR consisted of 12.5 mlR T
2 SYBR Green/ROX qPCR
MasterMix (Cat # PA-012-24, SABiosciences, QIAGEN), 6.5 ml
RNase-free water and 1 ml Primer Mix. PCRs for each gene of
interest were run in triplicate using the StepOne
TM Real-Time
PCR System (Applied Biosystems
TM). The PCR cycling program
was as follows: 95uC for 10 min and 40 cycles of 95uC for 15 s and
60uC for 1 min. The melt curve program was as follows: 95uC for
15 s, 60uC for 1 min, 65uCt o9 5 uCa t2 uC/min and 95uC for
12 s.
For validation of the primers, after each PCR cycling program a
default melting program was run to make sure that disassociation
curves for each pair of primers contained a single peak and the
agorose gels of the amplified product revealed single band
corresponding to the predictable amplicon length. To determine
Table 1. Primary antibodies used for
immunohistochemistrical staining.
Target
Dilution
ratio
Catalog
# Supplier
Anti-MBP (C-16) Myelin 1:1000 Sc-13914 Santa Cruz
Anti-GST-p Mature OL 1:1000 610719 BD Biosciences
Anti-GFAP Astrocyte 1:1000 MAB360 Millipore
Anti-CD140a PDGFR-a/OPC 1:500 558774 BD Biosciences
Abbreviations: MBP – myelin basic protein; GST-p – Glutathione S-Transferase p
form; GFAP – glial fibrillary acidic protein; PDGFR-a – alpha-type platelet-
derived growth factor receptor; OPC – oligodendrocyte precursor cell; OL –
oligodendrocyte.
doi:10.1371/journal.pone.0033901.t001
Figure 6. RNA sample sources. The illustration on the left represents the mouse brain. The top dashed line represents the first coronal cut, 5 mm
away from the edge of olfactory bulb. The bottom dashed line represents the second coronal cut, 2.5 mm away from the first cut. The illustration on
the right represents the brain section isolated on the left. The tissue within the dashed rectangle, containing mainly corpus callosum and part of the
cortex, was used for RNA extraction. Abbreviations: CC – corpus callosum; LV – lateral ventricle; aca – anterior commissure.
doi:10.1371/journal.pone.0033901.g006
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the initiation of the experiments with excellent results.
Data collection and processing
The body weight of the experimental animals was monitored
twice a week. Body weight increases of the individual mice were
calculated in terms of percentage of body weight increase
compared to the initial body weight.
IHC staining slides were digitally captured using a ZEISS
AxioImager A1 light microscope equipped with an AxioCam
ICC3 digital camera, as well as with an OLYMPUS BH-2 light
microscope equipped with an OLYMPUS Q-color5 digital
camera. The software programs used for these two microscopes
were AxioVision Rel. 4.8 version (Carl Zeiss) and ImagePro Plus
5.0 version (MediaCybernetics), respectively. The MBP-immuno-
staining revealed many fine fibers, which ran parallel to the cortex
and were heavily condensed in the CC. We measured the optical
density of the MBP-immunostaining according to NIH ImageJ
protocols for quantitative comparison [42]. Because the intensity
of the DAB color varied slightly between samples (due to natural
variations between similarly treated samples), the optical density
measurements were standardized for color intensity using the
optical density of the aca (as demonstrated by the single-arrow in
Fig. 2), an area where MBP staining was consistent, regardless of
CPZ challenge. All of these data collection methods were also
applied to PDGFR-a staining because proliferation of the positive
cells in the experimental groups increased so dramatically that we
could not accurately count them. Analysis of GST-p staining was
based on actual counts by an experimental-blind personnel on
whole fields of view.
Statistical analysis
The statistic calculations and graphs were made using
GraphPad PrismH version 5. Body weight data were analyzed
using two-factor mix-measures analysis of variance (two-factor
mix-measures ANOVA) assuming that genotype was the factor for
independent grouping and that time elapsed was the other factor
for repeated measures. All IHC data were analyzed using two-way
independent ANOVA assuming that genotype was the factor for
independent grouping and using groupings for different levels of
experimental manipulation as another independent factor. All
two-way ANOVA tests were accompanied by Bonferroni’s
multiple comparison tests. When considering variances caused
by either factor (e.g., body weight changes within WT groups) one-
factor ANOVA tests accompanied by Tukey’s multiple compar-
ison tests were applied. A p-value less than 0.05 (difference/effect)
was considered to be significant.
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